• Description
• Additional information
• Reviews (0)

ARA-290 (Cibinetide) 10 mg

Innate Repair Receptor Research Peptide | Non-Erythropoietic EPO-Mimetic | RUO

11-Amino Acid | MW 1,257.3 g/mol | PubChem CID 91810664 | CAS 1208243-50-8 | Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser | Lyophilized | COA Per Batch

FOR RESEARCH USE ONLY. Not intended for consumption, parenteral administration, therapeutic, or diagnostic application of any kind. For laboratory and preclinical research exclusively.

TECHNICAL SPECIFICATIONS

Technical Specifications	Data
Product Reference	ARA-290 (Cibinetide) 10 mg Innate Repair Receptor Research Peptide
Also Known As	Cibinetide | pHBSP | PH-BSP | Pyroglutamate Helix-B Surface Peptide | UEQLERALNSS
INN (Nonproprietary)	Cibinetide (USAN/INN — Araim Pharmaceuticals)
Chemical Class	Synthetic Linear Peptide — Non-Erythropoietic EPO-Mimetic IRR Agonist
PubChem CID	91810664
CAS Registry	1208243-50-8
DrugBank	DB13006
ChEMBL	ChEMBL3545305
Molecular Formula	CnnHnnNnnOnn
Molecular Weight	1,257.3 g/mol
Sequence (1-letter)	ZEQLERALNSS (Z = pyroglutamate)
Sequence (3-letter)	pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Amino Acid Count	11 residues
Receptor Target	IRR: EPOR/CD131 (b-common receptor) heterodimer — Selective agonist
Erythropoietic Activity	None — selective non-haematopoietic IRR profile
Physical Format	Lyophilized Powder — Hermetically Sealed Container — 10 mg per batch
Analytical Purity	≥99% (RP-HPLC verified)
Identity Confirmation	LC-MS — molecular weight and sequence verified per batch
Endotoxin Screening	<0.25 EU/mg (LAL method)
Reconstitution	Sterile aqueous buffer (PBS or bacteriostatic water)
Storage — Lyophilized	2–8°C, desiccated, light-protected
Storage — Reconstituted	-20°C, single-use aliquots; avoid repeated freeze-thaw
Regulatory Class	Research Use Only (RUO) — Not for administration to living organisms
COA Availability	Per-batch COA downloadable from Profound Aminos COA portal

Disclaimer : For Research Use Only (RUO). Not for human use.

PRODUCT OVERVIEW

Cibinetide (ARA-290) was rationally engineered by Araim Pharmaceuticals to isolate the tissue-protective signalling activity of erythropoietin while eliminating erythropoietic risk. The 11-residue sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser — corresponds to the helix-B surface domain of native EPO (residues 11-15 and 100-108 in tertiary proximity) that contacts the EPOR/CD131 heterodimer interface. The pyroglutamate residue at position 1 confers N-terminal cyclisation, providing resistance to aminopeptidase degradation. Arginine at position 6 (equivalent to EPO Arg-103) is critical for IRR receptor engagement and hydrogen-bonding within the CD131 binding groove.

In preclinical research models, IRR activation by cibinetide initiates a signalling cascade that diverges fundamentally from classical EPOR homodimer pathways. Rather than driving erythroid differentiation, IRR engagement activates JAK2 and downstream STAT5/MAPK cascades in non-haematopoietic tissues — resulting in inhibition of NF-kB p65 nuclear translocation, suppression of pro-inflammatory cytokine production (IL-6, TNF-a, IL-12), reduction in myeloid cell tissue infiltration, and upregulation of anti-apoptotic gene programs. This mechanistic profile positions ARA-290 as the primary IRR agonist research tool in 2026-era inflammation, neuroprotection, and tissue-integrity pathway research.

MOLECULAR STRUCTURE – PubChem CID 91810664

ARA-290 (Cibinetide) 11-Amino Acid Peptide Backbone & Mechanism Schematic | Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser | PubChem CID 91810664 | CnnHnnNnnOnn | MW 1,257.3 g/mol | CAS 1208243-50-8 | Teal residues = pharmacologically critical positions | Non-Erythropoietic IRR Agonist Research Reagent

ARA-290 (Cibinetide) – PubChem CID 91810664

Cibinetide has molecular formula C51H84N16O21 and molar mass 1,257.3 g/mol (PubChem CID 91810664; CAS 1208243-50-8; DrugBank DB13006; ChEMBL3545305; KEGG D11218). The 11-residue linear peptide sequence is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (single-letter: ZEQLERALNSS). The N-terminal pyroglutamate (pGlu, Z) is formed by cyclisation of glutamine and provides proteolytic stability at the N-terminus.

Arginine at position 6 corresponding to Arg-103 of native human EPO — is essential for IRR receptor engagement at the EPOR/CD131 heterodimer binding interface. The peptide contains 16 nitrogen atoms reflecting the high arginine, glutamine, and asparagine content characteristic of receptor-binding peptides. Computed properties: 13 hydrogen-bond donors, 23 acceptors, topological polar surface area ~528 Å2, consistent with a hydrophilic, aqueous-soluble research peptide.

RESEARCH MECHANISM — 2026 LABORATORY APPLICATIONS

In 2026-era neuroimmunology, tissue-injury biology, and IRR pharmacology research, cibinetide is utilised to investigate the following mechanistic pathways:

1. Selective IRR (EPOR/CD131) Receptor Agonism — Receptor Pharmacology Research
   Investigating how ARA-290 selectively binds the EPOR/b-common receptor (CD131) heterodimer (the innate repair receptor, IRR) without engaging EPOR homodimers responsible for erythropoiesis. Research applications include IRR binding affinity quantification, competitive displacement assays using radiolabelled EPO analogues, receptor saturation studies in EPOR/CD131-expressing cell lines, and confirmation of non-erythropoietic receptor selectivity via haemoglobin and reticulocyte assays in preclinical rodent models.
2. NF-kB Inhibition & Pro-Inflammatory Cytokine Suppression Research
   Studying how IRR activation by cibinetide inhibits nuclear translocation of NF-kB p65 subunit in myeloid cells and downstream transcription of pro-inflammatory mediators including IL-6, TNF-a, IL-12, nitric oxide synthase-2 (NOS2), and chemokine CXCL-10. Research endpoints include electrophoretic mobility shift assays (EMSA) for NF-kB DNA binding, ELISA cytokine quantification panels, flow cytometric myeloid cell activation markers, and NOS2 enzyme activity assays in LPS-stimulated macrophage and monocyte culture models.
3. JAK2-STAT5 / MAPK Downstream Signalling Pathway Research
   Quantifying how IRR engagement by ARA-290 activates JAK2 kinase and downstream STAT5 phosphorylation in non-haematopoietic tissues — initiating anti-apoptotic gene programs and MAPK cascade activation. Research applications include Western blot phosphoprotein profiling (pJAK2, pSTAT5, pERK1/2), co-immunoprecipitation of EPOR/CD131 receptor complex, kinase inhibitor competition assays, and STAT5 transcriptional reporter systems in neuronal and endothelial cell models.
4. Nociceptive Pathway & TRPV1 Modulation Research
   Investigating the anti-nociceptive mechanism of ARA-290 in preclinical neuropathy models — specifically its modulation of TRPV1 (transient receptor potential vanilloid 1) channel sensitisation in primary afferent neurons. Research applications include dorsal root ganglion (DRG) neuron calcium imaging, TRPV1 current recordings via patch-clamp electrophysiology, von Frey mechanical allodynia assays in rodent neuropathy models, and spinal cord microglial activation quantification (Iba-1 immunohistochemistry) based on published preclinical findings by Brines et al.
5. Tissue-Protective & Anti-Apoptotic Pathway Research
   Studying how IRR-mediated signalling activates anti-apoptotic gene programs in tissues experiencing ischaemia-reperfusion injury, inflammatory stress, or mechanical trauma. Research applications include caspase-3/7 activity assays, TUNEL-based apoptosis quantification, mitochondrial membrane potential measurement (JC-1 assay), ATP-level bioluminescence assays in cibinetide-treated human islet culture models (referenced from Watanabe et al., Transplantation 2016), and endothelial barrier integrity measurement in transwell permeability assays.
6. Innate Immune Modulation & Myeloid Cell Infiltration Research
   Investigating how cibinetide reduces myeloid cell tissue infiltration and inflammatory mediator production in experimental colitis, myocardial injury, and neural trauma models. Based on published findings from a 2017 Scientific Reports colitis study demonstrating CD131- and JAK2-dependent reduction in myeloid infiltration and NF-kB activation, research applications include histological quantification of tissue-resident macrophage and neutrophil counts, myeloperoxidase activity assays, and multiplex cytokine panel analysis in cibinetide-treated inflammatory disease models.
7. Cardiovascular Ageing & Cardiac Function Preservation Research
   Studying how chronic ARA-290 exposure modulates age-related cardiac inflammatory decline, based on a 2023 randomised controlled trial in Fischer 344 × Brown Norway ageing rats (PMC9889362) demonstrating attenuation of leukocyte infiltration, reduction in NF-kB activation, enhanced cardiomyocyte autophagy, and preserved left-ventricular ejection fraction. Research applications include echocardiographic functional assessment in aged rodent models, cardiomyocyte autophagy flux measurement (LC3B-II/LC3B-I ratio), mitochondrial permeability transition pore (mPTP) assays, and cardiac cytokine profiling.
8. Pancreatic Islet Transplantation Protection Research
   Investigating IRR-mediated protection of transplanted pancreatic islets from inflammatory macrophage activation and alloimmune rejection — based on published preclinical data (Watanabe et al. 2016, Yao et al. 2020) showing cibinetide maintained ATP levels,bsuppressed caspase 3/7 activity in human islets under cytokine stress, improved engraftment (higher human insulin in recipient liver at day 6), and reduced IL-1 and IL-6 mRNA expression. Research endpoints include islet viability staining, insulin secretion ELISA, allo-reactive IFN-g ELISpot assays, and islet allograft survival curves in rodent transplant models.

WHY SOURCE FROM PROFOUND AMINOS

1. Sequence-Confirmed Identity via LC-MS
   ARA-290 is an 11-residue peptide. Standard purity testing confirms what percentage of a container is the target compound it does not confirm the correct amino acid sequence. For a peptide with a N-terminal pyroglutamate (which can artefactually form from glutamine during synthesis), sequence confirmation is not optional. Profound Aminos verifies every batch via LC-MS molecular weight confirmation (expected [M+H]+ 1258.3) and peptide sequence mapping. Both RP-HPLC purity (³99%) and LC-MS identity are reported on every per-batch COA. Purity without sequence identity is an incomplete quality standard.
2. Lyophilized 10 mg Format — Research-Grade Stability
   Peptides containing asparagine (position 9 in ARA-290) are susceptible to deamidation in aqueous solution over time, generating isoaspartate artefacts that can confound receptor binding assays. Lyophilized storage eliminates aqueous degradation pathways, preserving peptide integrity across the research inventory lifecycle. The 10 mg lyophilized batch size provides sufficient material for multiple reconstitution cycles at standard laboratory research concentrations, with each aliquot prepared fresh from a characterised, stable starting material.
3. Endotoxin Screening — Critical for IRR Research Models
   LPS endotoxin is a potent NF-kB activator via Toll-like receptor 4 (TLR4). Because ARA-290’s primary research endpoint is NF-kB inhibition via the IRR pathway, unscreened endotoxin contamination would directly confound dose-response relationships making it impossible to distinguish IRR-mediated NF-kB suppression from LPS-driven activation. Every Profound Aminos ARA-290 batch is screened to <0.25 EU/mg by LAL chromogenic method, documented on the COA. For NF-kB research, this is a non-negotiable quality standard.
4. USA Domestic Cold-Chain — No Customs Degradation Risk
   Peptides are thermally sensitive. International sourcing introduces uncontrolled temperature excursions during customs holding that degrade asparagine-containing sequences via deamidation — at exactly the residues most relevant to receptor binding. Profound Aminos ships ARA-290 exclusively within the USA via monitored cold-chain logistics from a climate-controlled facility to your research address.

COMPARATIVE RESEARCH CONTEXT — 2026 IRR Agonist Research Landscape

Feature	ARA-290 (Cibinetide)	Full-Length EPO	EPO-Fc Fusions	BPC-157
Chemical Class	11-AA Synthetic Peptide	166-AA Glycoprotein	EPO-Fc Conjugate	15-AA Synthetic Peptide
Receptor	IRR (EPOR/CD131 het.)	EPOR Homodimer + IRR	EPOR Homodimer	Multiple (non-IRR)
Erythropoietic Activity	None (non-haematopoietic)	High — RBC production	High — RBC production	None
IRR Selectivity	Selective — high	Non-selective	Non-selective	Not applicable
PubChem CID	91810664	N/A (biologic)	N/A (conjugate)	107734
Research Half-Life	~30 min (preclinical)	~8 hours	Extended (days)	Variable
Orphan Designation	FDA + EMA (sarcoidosis)	Multiple approved	None	None
NF-kB Inhibition	Documented (CD131/JAK2)	Partial (mixed signal)	Partial	Separate mechanism
2026 FDA Status	Investigational — No approval	Multiple approved products	No US approval	No US approval

FREQUENTLY ASKED QUESTIONS

Q1: Is ARA-290 (Cibinetide) intended for consumption or administration?

No. ARA-290 (cibinetide) is strictly classified as a Research Use Only (RUO) laboratory reagent. It is not approved, labelled, or intended for consumption, parenteral administration, therapeutic use, or any diagnostic application. Purchase confirms agreement to institutional laboratory research use only. Any use outside a qualified laboratory setting violates our Terms of Service and U.S. federal law.

Q2: What is the innate repair receptor (IRR) and why does it matter in research?

The innate repair receptor (IRR) is a heterodimeric receptor complex composed of the erythropoietin receptor (EPOR) and the b-common receptor CD131 (also known as CSF2RB). Unlike the EPOR homodimer which drives erythropoiesis in bone marrow the IRR is expressed predominantly in non-haematopoietic tissues including peripheral nerves, endothelium, cardiac tissue, and myeloid immune cells. It is rapidly upregulated following tissue injury. IRR activation initiates JAK2/STAT5 and MAPK signalling that produces anti-apoptotic and anti-inflammatory responses without erythropoietic activity, making it a scientifically distinct target from classical EPO receptor research.

Q3: What is the difference between ARA-290 and full-length erythropoietin (EPO)?

Full-length EPO is a 166-amino acid glycoprotein that activates both EPOR homodimers (driving red blood cell production in bone marrow) and the IRR heterodimer in peripheral tissues. ARA-290 (cibinetide) is an 11-residue synthetic peptide derived from EPO’s helix-B surface domain. It selectively activates the IRR without engaging EPOR homodimers and consequently produces no erythropoietic effect — no haemoglobin elevation, no haematocrit increase, and no thromboembolic risk — making it a clean tool
compound for studying the IRR pathway in isolation from erythropoietic confounds.

Q4: What are the key chemical identifiers for ARA-290 (Cibinetide)?

PubChem CID: 91810664 | Molecular Formula: CnnHnnNnnOnn | Molecular Weight: 1,257.3 g/mol | CAS Registry Number: 1208243-50-8 | DrugBank: DB13006 | ChEMBL: ChEMBL3545305 | KEGG: D11218 | UNII: 9W5677JKDA | INN: Cibinetide | Sequence (1-letter): ZEQLERALNSS | Sequence (3-letter): pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser.

These identifiers are retrievable from the PubChem compound record at pubchem.ncbi.nlm.nih.gov/compound/91810664.

Q5: How is ARA-290 reconstituted for laboratory use?

Reconstitute lyophilized ARA-290 in sterile PBS or bacteriostatic water at the molar concentration required for the specific assay protocol. Calculate target concentration using MW 1,257.3 g/mol. For a 1 mg/mL stock solution: dissolve the lyophilized powder in 10 mL sterile buffer per 10 mg batch. Reconstitute by adding solvent slowly along the container wall with gentle swirling — do not vortex. Aliquot immediately into single-use research volumes and store at -20°C. Protect from light. Avoid repeated freeze-thaw cycles which accelerate asparagine deamidation at position 9.

Q6: What is the FDA regulatory status of ARA-290 (Cibinetide) in 2026?

As of May 2026, ARA-290 (cibinetide) has no FDA marketing approval for any human indication. The FDA granted orphan drug designation for sarcoidosis-associated neuropathic pain (September 2011) and fast track designation — these provide development incentives and do not constitute approval. No NDA or BLA was filed by Araim Pharmaceuticals before the company ceased active development operations. No active IND for ARA-290 is currently registered in the USA as of May 2026.

The compound appears in FDA’s bulk drug substance nomination documentation for 503A/503B compounding consideration, but nomination is explicitly distinguished from placement on a positive bulks list. Cibinetide is not on the 503A or 503B positive bulks lists as of May 2026. Profound Aminos supplies ARA-290 exclusively as an RUO research reagent under 21 CFR 312.2(b)(1). Any use for human application is prohibited.

Q7: Is there published clinical research on ARA-290 (Cibinetide)?

Yes -early-phase and Phase 2 clinical investigations were conducted, though no pivotal Phase 3 trial was completed. Key published studies include: a Phase 2b trial in sarcoidosis-associated small fiber neuropathy (SFN) showing increased corneal nerve fiber density and reduced neuropathic pain scores (Brines et al., PMC3563705); a Phase 2 trial in type 2 diabetes neuropathy showing improved metabolic control and neuropathic pain (PMID: 25387363, Mol Med 2015); and a Phase 2 pilot in diabetic macular oedema showing acceptable safety profile (PMC7408632). These findings are Phase 2 and do not constitute evidence for regulatory approval or therapeutic use.

Q8: What preclinical research models have been used with ARA-290?

Published preclinical research includes: dextran-sulphate-sodium colitis model (Scientific Reports 2017, PMC cited); neuropathic pain allodynia models in b-common receptor knockout mice (TRPV1/ARA-290 mechanism, PubMed); 15-month ageing rat cardiac function study (Fischer 344 × Brown Norway rats, PMC9889362); pancreatic islet transplantation models — human islet ATP/caspase assays and allograft survival (Watanabe et al. ATC 2017, Yao et al. Transplantation 2020); myocardial infarction, ischaemic stroke, peripheral nerve trauma, wound healing, and haemorrhagic shock models; and atherosclerosis suppression in hyperlipidaemic rabbits. Research endpoints include myeloid cell infiltration histology, NF-kB EMSA, cytokine ELISA panels, von Frey mechanical allodynia, ejection fraction echocardiography, and corneal confocal microscopy.

Q9: Do you provide a COA for every ARA-290 batch?

Yes. Every ARA-290 (Cibinetide) batch from Profound Aminos includes a Certificate of Analysis documenting: RP-HPLC purity (³99%), LC-MS molecular weight and sequence identity confirmation, endotoxin screening result (<0.25 EU/mg by LAL chromogenic method), lot number, manufacturing date, and storage conditions. Available for download per batch from the Profound Aminos COA portal prior to or upon order. Third-party analytical verification on request.

Q10: What is ARA-290’s EMA regulatory status and orphan designation history?

The European Medicines Agency (EMA) granted cibinetide orphan designation EU/3/13/1191 on 7 October 2013 for the treatment of sarcoidosis. The EMA description identifies cibinetide as L-pGlu-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser. Additional orphan designations were granted for prevention of graft loss in pancreatic islet transplantation and related indications. Orphan designation provides market exclusivity incentives and development assistance for rare disease applications but does not constitute marketing authorisation. As of May 2026, cibinetide holds no EMA marketing authorisation. The compound remains investigational in all jurisdictions. RUO material supplied by Profound Aminos is not an approved medicine in any jurisdiction.

REGULATORY & COMPLIANCE STATEMENT (RUO)

Category	Statement
Regulatory Status	Research Use Only (RUO) — U.S. Federal Regulatory Framework | 21 CFR 312.2(b)(1)
FDA Status (May 2026)	Not approved. No NDA/BLA filed. No active IND registered. Orphan Drug Designation (sarcoidosis-associated neuropathic pain, 2011) and Fast Track Designation granted — these are NOT approvals. Nominated for 503A/503B bulk list review — nomination ≠ placement on positive bulks list. Not on 503A or 503B positive list as of May 2026.
EMA Status (May 2026)	Orphan Designation EU/3/13/1191 (sarcoidosis, Oct 2013) — NOT a marketing authorisation. No EMA marketing approval in any indication as of May 2026.
Compounding Status	Not on 503A or 503B positive bulks list. Compounding of cibinetide for human use is not generally permitted under current FDA guidance.
Not a Drug	Not evaluated by FDA for safety or efficacy. No approved indication.
Not a Supplement	Not a dietary supplement, nutraceutical, or consumer product.
Chemical Reference	Supplied solely for laboratory testing and preclinical scientific investigation.
PPE Required	Gloves, lab coat, and protective eyewear during reconstitution and handling.
Key References	PubChem CID 91810664 | CAS 1208243-50-8 | DrugBank DB13006 | ChEMBL3545305

STRICT PROHIBITION: Promoting, distributing, or using this research reagent for any application involving administration to living organisms is strictly prohibited and constitutes a violation of U.S. federal law. FDA enforcement actions in 2024–2026 have established that RUO disclaimers do not protect vendors when overall marketing content indicates intended human use.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

KEY REFERENCES – PubMed / PubChem / Regulatory Verified

#	Citation	Relevance
1	Brines M et al. ARA 290 in sarcoidosis SFN — Phase 2b pilot. Safety and efficacy of ARA 290 in sarcoidosis with small fiber neuropathy. PMC3563705.	Primary Phase 2b sarcoidosis SFN trial — corneal nerve density + pain endpoints
2	Niesters M et al. ARA 290 improves metabolic control and neuropathic symptoms in type 2 diabetes. Mol Med 2015. PMID: 25387363.	Phase 2 diabetic neuropathy — metabolic + neuropathic pain outcomes
3	Lois N et al. Phase 2 clinical trial — cibinetide for diabetic macular edema. PMC7408632. J Clin Med 2020.	Phase 2 pilot DME trial — safety and preliminary efficacy
4	Watanabe M et al. Cibinetide improves engraftment in pancreatic islet transplantation. Am J Transplant 2017 (ATC Abstracts).	Islet transplant protection — ATP/caspase assay, allograft survival
5	Wang Z et al. ARA-290 cardiac ageing study — 15-month Fischer 344xBN rat RCT. PMC9889362. Aging 2023.	Cardiac function preservation in aged rats — LV ejection fraction, NF-kB, autophagy
6	Cibinetide dampens innate immune cell functions — experimental colitis. Scientific Reports 2017. doi:10.1038/s41598-017-13046-3.	NF-kB inhibition, myeloid cell infiltration — CD131/JAK2-dependent mechanism
7	Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the innate repair receptor to treat neuropathy. Pain Reports 2016.	IRR as clinically actionable target — neuropathy mechanism review
8	PubChem CID 91810664 — Cibinetide. pubchem.ncbi.nlm.nih.gov/compound/91810664. Updated May 17, 2026.	Chemical identity, molecular formula, computed properties — authoritative registry
9	FDA Bulk Drug Substances Nominated for Compounding 503A/503B — May 2026 update. FDA.gov/media/94155/download.	Cibinetide nominated for compounding review — not on positive bulks list
10	EMA Orphan Designation EU/3/13/1191 — Cibinetide for sarcoidosis. Oct 7, 2013.	EU orphan designation — not a marketing authorisation
11	Google Ads Policy — Unapproved Pharmaceuticals 2026 | YMYL/E-E-A-T Guidelines 2026.	Platform advertising compliance and content quality framework

Weight	0.02 lbs
Dimensions	1.5 × 2.75 × 1 in
Strength	10mg

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

DISCLAIMER:

• Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited. They must also not be misbranded, misused, or mislabeled, or used for anything other than research and scientific investigation.
• All the products you see on the website are being sold in a lyophilized powder state (freeze-dried), in a sealed sterile vial; and should be reconstituted.
  The product’s label clearly states the amount of product a vial contains; some products are offered in different variations.
• The products we are selling come in a sealed vial but require additional lab equipment for proper testing. 
• Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.